Identification

Name
Maprotiline
Accession Number
DB00934  (APRD00747)
Type
Small Molecule
Groups
Approved, Investigational
Description

Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does not appear to block serotonin reuptake. Maprotiline may be used to treat depressive affective disorders, including dysthymic disorder (depressive neurosis) and major depressive disorder. Maprotiline is effective at reducing symptoms of anxiety associated with depression.

Structure
Thumb
Synonyms
  • Maprotilina
  • Maprotilinum
  • Maprotylina
Product Ingredients
IngredientUNIICASInChI Key
Maprotiline Hydrochloride7C8J54PVFI10347-81-6NZDMFGKECODQRY-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ludiomil Tab 10mgTablet10 mgOralNovartis1985-12-312003-07-29Canada
Ludiomil Tab 25mgTablet25 mgOralNovartis1976-12-312001-07-30Canada
Ludiomil Tab 50mgTablet50 mgOralNovartis1976-12-312001-07-30Canada
Ludiomil Tab 75mgTablet75 mgOralNovartis1976-12-312000-08-02Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Maprotiline HydrochlorideTablet, film coated25 mg/1OralMylan Pharmaceuticals1988-10-03Not applicableUs
Maprotiline HydrochlorideTablet, film coated75 mg/1OralMylan Pharmaceuticals1988-10-03Not applicableUs
Maprotiline HydrochlorideTablet, film coated50 mg/1OralMylan Pharmaceuticals1988-10-03Not applicableUs
Novo-maprotiline - Tab 10mgTablet10 mgOralNovopharm Limited1995-12-312005-08-10Canada
PMS-maprotilineTablet25 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-maprotilineTablet75 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-maprotilineTablet10 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-maprotilineTablet50 mgOralPharmascience IncNot applicableNot applicableCanada
Teva-maprotilineTablet75 mgOralTeva1995-12-31Not applicableCanada
Teva-maprotilineTablet25 mgOralTeva1995-12-31Not applicableCanada
International/Other Brands
Deprilept / Ludiomil / Psymion
Categories
UNII
2U1W68TROF
CAS number
10262-69-8
Weight
Average: 277.4033
Monoisotopic: 277.183049741
Chemical Formula
C20H23N
InChI Key
QSLMDECMDJKHMQ-UHFFFAOYSA-N
InChI
InChI=1S/C20H23N/c1-21-14-6-12-20-13-11-15(16-7-2-4-9-18(16)20)17-8-3-5-10-19(17)20/h2-5,7-10,15,21H,6,11-14H2,1H3
IUPAC Name
methyl(3-{tetracyclo[6.6.2.0²,⁷.0⁹,¹⁴]hexadeca-2,4,6,9,11,13-hexaen-1-yl}propyl)amine
SMILES
CNCCCC12CCC(C3=CC=CC=C13)C1=CC=CC=C21

Pharmacology

Indication

For treatment of depression, including the depressed phase of bipolar depression, psychotic depression, and involutional melancholia, and may also be helpful in treating certain patients suffering severe depressive neurosis.

Structured Indications
Pharmacodynamics

Maprotiline is a tetracyclic antidepressant. Although its main therapeutic use is in the treatment of depression, it has also been shown to exert a sedative effect on the anxiety component that often accompanies depression. In one sleep study, it was shown that maprotiline increases the duration of the REM sleep phase in depressed patients, compared to imipramine which reduced the REM sleep phase. Maprotiline is a strong inhibitor of noradrenaline reuptake in the brain and peripheral tissues, however it is worthy to note that it is a weak inhibitor of serotonergic uptake. In addition, it displays strong antihistaminic action (which may explain its sedative effects) as well as weak anticholinergic action. Maprotiline also has lower alpha adrenergic blocking activity than amitriptyline.

Mechanism of action

Maprotiline exerts its antidepressant action by inhibition of presynaptic uptake of catecholamines, thereby increasing their concentration at the synaptic clefts of the brain. In single doses, the effect of maprotiline on the EEG revealed a rise in the alpha-wave density, a reduction of the alpha-wave frequency and an increase in the alpha-wave amplitude. However, as with other tricyclic antidepressants, maprotiline lowers the convulsive threshold. Maprotiline acts as an antagonist at central presynaptic α2-adrenergic inhibitory autoreceptors and hetero-receptors, an action that is postulated to result in an increase in central noradrenergic and serotonergic activity. Maprotiline is also a moderate peripheral α1 adrenergic antagonist, which may explain the occasional orthostatic hypotension reported in association with its use. Maprotiline also inhibits the amine transporter, delaying the reuptake of noradrenaline and norepinephrine. Lastly, maprotiline is a strong inhibitor of the histamine H1 receptor, which explains its sedative actions.

TargetActionsOrganism
ASodium-dependent noradrenaline transporter
inhibitor
Human
NHistamine H1 receptor
antagonist
Human
NMuscarinic acetylcholine receptor M1
antagonist
Human
NMuscarinic acetylcholine receptor M2
antagonist
Human
NMuscarinic acetylcholine receptor M3
antagonist
Human
NMuscarinic acetylcholine receptor M4
antagonist
Human
NMuscarinic acetylcholine receptor M5
antagonist
Human
NAlpha-1 adrenergic receptors
antagonist
Human
U5-hydroxytryptamine receptor 2A
binder
Human
U5-hydroxytryptamine receptor 2C
binder
Human
U5-hydroxytryptamine receptor 7
antagonist
Human
UD(2) dopamine receptor
binder
Human
UAlpha-2 adrenergic receptors
antagonist
Human
Absorption

Slowly, but completely absorbed from the GI tract following oral administration.

Volume of distribution

Maprotiline and its metabolites may be detected in the lungs, liver, brain, and kidneys; lower concentrations may be found in the adrenal glands, heart and muscle. Maprotiline is readily distributed into breast milk to similar concentrations as those in maternal blood.

Protein binding

88%

Metabolism

Hepatic. Maprotiline is metabolized by N-demethylation, deamination, aliphatic and aromatic hydroxylations and by formation of aromatic methoxy derivatives. It is slowly metabolized primarily to desmethylmaprotiline, a pharmacologically active metabolite. Desmethylmaprotiline may undergo further metabolism to maprotiline-N-oxide.

Route of elimination

Approximately 60% of a single orally administered dose is excreted in urine as conjugated metabolites within 21 days; 30% is eliminated in feces.

Half life

Average ~ 51 hours (range: 27-58 hours)

Clearance
Not Available
Toxicity

LD50=~900 mg/kg (Orally in rats); LD50=90 mg/kg (Orally in women); Signs of overdose include motor unrest, muscular twitching and rigidity, tremor, ataxia, convulsions, hyperpyrexia, vertigo, mydriasis, vomiting, cyanosis, hypotension, shock, tachycardia, cardiac arrhythmias, impaired cardiac conduction, respiratory depression, and disturbances of consciousness up to deep coma.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Maprotiline is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Maprotiline.Experimental
AbirateroneThe serum concentration of Maprotiline can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Aceprometazine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Acetophenazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Maprotiline is combined with Adipiplon.Investigational
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Maprotiline.Approved
AgomelatineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Maprotiline is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Maprotiline.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Maprotiline.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Maprotiline is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Maprotiline.Approved, Illicit, Investigational
AmiodaroneThe metabolism of Maprotiline can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Maprotiline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Maprotiline.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Maprotiline.Approved
AmperozideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Amperozide.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Maprotiline.Approved, Illicit, Investigational
AnagrelideMaprotiline may increase the QTc-prolonging activities of Anagrelide.Approved
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Maprotiline.Approved, Investigational
Arsenic trioxideMaprotiline may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherMaprotiline may increase the QTc-prolonging activities of Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Articaine.Approved
AsenapineMaprotiline may increase the QTc-prolonging activities of Asenapine.Approved
AtomoxetineThe metabolism of Maprotiline can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Azaperone.Investigational, Vet Approved
AzelastineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinThe metabolism of Maprotiline can be decreased when combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Maprotiline.Approved
BarbitalThe risk or severity of adverse effects can be increased when Maprotiline is combined with Barbital.Illicit
BedaquilineMaprotiline may increase the QTc-prolonging activities of Bedaquiline.Approved
BenmoxinThe risk or severity of adverse effects can be increased when Benmoxin is combined with Maprotiline.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Maprotiline is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Benzocaine.Approved, Investigational
Benzyl alcoholThe risk or severity of adverse effects can be increased when Maprotiline is combined with Benzyl alcohol.Approved
BetaxololThe metabolism of Maprotiline can be decreased when combined with Betaxolol.Approved, Investigational
BifeprunoxThe risk or severity of adverse effects can be increased when Maprotiline is combined with Bifeprunox.Investigational
BortezomibThe metabolism of Maprotiline can be decreased when combined with Bortezomib.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Maprotiline.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Maprotiline.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Maprotiline is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Brofaromine is combined with Maprotiline.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Maprotiline.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Maprotiline is combined with Bromisoval.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Maprotiline is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Maprotiline.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Maprotiline is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Bupivacaine.Approved, Investigational
BuprenorphineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Maprotiline can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Maprotiline.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Maprotiline.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Maprotiline.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Maprotiline is combined with Butamben.Approved
ButaperazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Maprotiline is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Maprotiline.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Maprotiline.Approved
CaffeineThe metabolism of Maprotiline can be decreased when combined with Caffeine.Approved
CanertinibThe risk or severity of adverse effects can be increased when Maprotiline is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Maprotiline.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Maprotiline.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Maprotiline is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Cariprazine.Approved, Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Maprotiline.Approved
CaroxazoneThe risk or severity of adverse effects can be increased when Caroxazone is combined with Maprotiline.Withdrawn
CelecoxibThe metabolism of Maprotiline can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibMaprotiline may increase the QTc-prolonging activities of Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Maprotiline.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Maprotiline is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Maprotiline.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Maprotiline can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Chlorphenamine.Approved
ChlorproethazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Chlorproethazine.Experimental
ChlorpromazineThe metabolism of Maprotiline can be decreased when combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Maprotiline.Approved
CholecalciferolThe metabolism of Maprotiline can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Maprotiline can be decreased when combined with Cimetidine.Approved, Investigational
CinacalcetThe metabolism of Maprotiline can be decreased when combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Cinchocaine.Approved, Vet Approved
CiprofloxacinMaprotiline may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideMaprotiline may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramMaprotiline may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinMaprotiline may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe metabolism of Maprotiline can be decreased when combined with Clemastine.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Maprotiline.Approved
ClobazamThe metabolism of Maprotiline can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Maprotiline is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Maprotiline is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Maprotiline.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Maprotiline is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Maprotiline.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Maprotiline can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Maprotiline can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Maprotiline can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Maprotiline can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Maprotiline.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Maprotiline.Approved
CrizotinibMaprotiline may increase the QTc-prolonging activities of Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Maprotiline.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Cyclopropane.Experimental
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Maprotiline.Approved
Cyproterone acetateThe serum concentration of Maprotiline can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Maprotiline.Approved
DantroleneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Dantrolene.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Maprotiline is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Maprotiline.Investigational
DarifenacinThe metabolism of Maprotiline can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Maprotiline can be increased when it is combined with Darunavir.Approved
DeferasiroxThe serum concentration of Maprotiline can be increased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Maprotiline can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Maprotiline.Approved
DesipramineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Desipramine.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Maprotiline.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Dexmedetomidine.Approved, Vet Approved
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Maprotiline.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Maprotiline.Approved, Illicit, Investigational, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Maprotiline is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Maprotiline is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Maprotiline.Approved, Illicit
DihydroergotamineThe risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Maprotiline.Approved, Investigational
DihydroetorphineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Maprotiline is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Maprotiline can be decreased when combined with Diphenhydramine.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Maprotiline.Approved, Illicit
DisopyramideMaprotiline may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Dixyrazine.Experimental
DofetilideMaprotiline may increase the QTc-prolonging activities of Dofetilide.Approved, Investigational
DolasetronMaprotiline may increase the QTc-prolonging activities of Dolasetron.Approved, Investigational
DomperidoneMaprotiline may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinThe risk or severity of adverse effects can be increased when Maprotiline is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Maprotiline can be decreased when combined with Dosulepin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Maprotiline is combined with Doxepin.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Maprotiline.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Maprotiline is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved, Illicit
DronedaroneMaprotiline may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Maprotiline is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Maprotiline.Approved
DyclonineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Maprotiline.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Maprotiline.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Maprotiline.Approved, Investigational
EliglustatMaprotiline may increase the QTc-prolonging activities of Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Maprotiline.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ergonovine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Maprotiline.Approved
ErythromycinMaprotiline may increase the QTc-prolonging activities of Erythromycin.Approved, Investigational, Vet Approved
EscitalopramMaprotiline may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Maprotiline.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Maprotiline.Approved, Investigational
EthanolMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Maprotiline.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Maprotiline.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Maprotiline is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Maprotiline is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Etorphine.Illicit, Vet Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Maprotiline.Approved
EzogabineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ezogabine.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Maprotiline is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Maprotiline.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Fexofenadine.Approved, Investigational
FlecainideMaprotiline may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Maprotiline is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Maprotiline is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Maprotiline is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Maprotiline can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolMaprotiline may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Maprotiline.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Maprotiline.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Maprotiline.Approved
FluvoxamineThe metabolism of Maprotiline can be decreased when combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Maprotiline is combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Maprotiline is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Maprotiline is combined with Frovatriptan.Approved, Investigational
FurazolidoneThe risk or severity of adverse effects can be increased when Furazolidone is combined with Maprotiline.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Maprotiline.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Maprotiline is combined with Gabapentin Enacarbil.Approved, Investigational
Gadobenic acidMaprotiline may increase the QTc-prolonging activities of Gadobenic acid.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Maprotiline.Approved, Illicit, Investigational
GemifloxacinMaprotiline may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Maprotiline is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Glutethimide.Approved, Illicit
GoserelinMaprotiline may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronMaprotiline may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Maprotiline is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Maprotiline can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Halothane.Approved, Vet Approved
HarmalineThe risk or severity of adverse effects can be increased when Harmaline is combined with Maprotiline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Maprotiline is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Maprotiline is combined with Hexobarbital.Approved
HydracarbazineThe risk or severity of adverse effects can be increased when Hydracarbazine is combined with Maprotiline.Experimental
HydrocodoneMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Maprotiline.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved
IbutilideMaprotiline may increase the QTc-prolonging activities of Ibutilide.Approved
IloperidoneMaprotiline may increase the QTc-prolonging activities of Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Maprotiline.Approved
IndalpineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Maprotiline can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Maprotiline is combined with Indiplon.Investigational
IproclozideThe risk or severity of adverse effects can be increased when Iproclozide is combined with Maprotiline.Withdrawn
IproniazidThe risk or severity of adverse effects can be increased when Iproniazid is combined with Maprotiline.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Maprotiline.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Maprotiline.Approved, Vet Approved
IsoniazidThe metabolism of Maprotiline can be decreased when combined with Isoniazid.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Maprotiline.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Maprotiline can be decreased when combined with Ketoconazole.Approved, Investigational
L-TryptophanL-Tryptophan may increase the serotonergic activities of Maprotiline.Approved, Nutraceutical, Withdrawn
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Maprotiline.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Maprotiline.Approved
LenvatinibMaprotiline may increase the QTc-prolonging activities of Lenvatinib.Approved, Investigational
LeuprolideMaprotiline may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Maprotiline is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Maprotiline is combined with Levodopa.Approved
LevofloxacinMaprotiline may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Maprotiline is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Maprotiline is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Maprotiline.Approved
LidocaineThe metabolism of Maprotiline can be decreased when combined with Lidocaine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Maprotiline.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Maprotiline is combined with Lithium.Approved
LobeglitazoneThe metabolism of Maprotiline can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Maprotiline is combined with Lofentanil.Illicit
LopinavirThe metabolism of Maprotiline can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Maprotiline is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Maprotiline.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Maprotiline.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Maprotiline is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Maprotiline is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Maprotiline.Approved
LumefantrineMaprotiline may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Maprotiline.Approved, Investigational
Magnesium SulfateThe therapeutic efficacy of Maprotiline can be increased when used in combination with Magnesium Sulfate.Approved, Investigational, Vet Approved
ManidipineThe metabolism of Maprotiline can be decreased when combined with Manidipine.Approved, Investigational
MebanazineThe risk or severity of adverse effects can be increased when Mebanazine is combined with Maprotiline.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Maprotiline is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Maprotiline.Approved
MedazepamThe risk or severity of adverse effects can be increased when Maprotiline is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Maprotiline is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Maprotiline.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Maprotiline is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Maprotiline.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Maprotiline.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Maprotiline is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Maprotiline.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Maprotiline.Approved
MethotrimeprazineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Methylecgonine.Experimental
Methylene blueMaprotiline may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Maprotiline is combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Metoclopramide.Approved, Investigational
MetoprololThe metabolism of Maprotiline can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineMaprotiline may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Maprotiline can be decreased when combined with Mexiletine.Approved, Investigational
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Maprotiline.Approved, Illicit
MidostaurinThe metabolism of Maprotiline can be decreased when combined with Midostaurin.Approved, Investigational
MifepristoneMifepristone may increase the QTc-prolonging activities of Maprotiline.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Maprotiline is combined with Milnacipran.Approved, Investigational
MinaprineThe risk or severity of adverse effects can be increased when Minaprine is combined with Maprotiline.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved, Investigational
MirabegronThe metabolism of Maprotiline can be decreased when combined with Mirabegron.Approved
MirtazapineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MoclobemideThe risk or severity of adverse effects can be increased when Moclobemide is combined with Maprotiline.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Moperone.Experimental
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Maprotiline.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Mosapramine.Experimental
MoxifloxacinMaprotiline may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Maprotiline.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Maprotiline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Maprotiline is combined with Naratriptan.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Nefazodone.Approved, Withdrawn
NevirapineThe metabolism of Maprotiline can be decreased when combined with Nevirapine.Approved
NialamideThe risk or severity of adverse effects can be increased when Nialamide is combined with Maprotiline.Withdrawn
NicardipineThe metabolism of Maprotiline can be decreased when combined with Nicardipine.Approved, Investigational
NilotinibMaprotiline may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Maprotiline.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Maprotiline.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Maprotiline.Approved
OctamoxinThe risk or severity of adverse effects can be increased when Octamoxin is combined with Maprotiline.Withdrawn
OfloxacinMaprotiline may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Maprotiline.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Maprotiline.Approved
OndansetronMaprotiline may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Maprotiline is combined with Opium.Approved, Illicit
OrphenadrineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Maprotiline is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Maprotiline can be decreased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Maprotiline.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Maprotiline is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Maprotiline.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Maprotiline.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Oxypertine.Experimental
PaliperidoneMaprotiline may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Maprotiline.Approved, Investigational
PanobinostatThe serum concentration of Maprotiline can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylineThe risk or severity of adverse effects can be increased when Pargyline is combined with Maprotiline.Approved
ParoxetineThe metabolism of Maprotiline can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Maprotiline.Approved
Peginterferon alfa-2bThe serum concentration of Maprotiline can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Maprotiline is combined with Penfluridol.Experimental
PentamidineMaprotiline may increase the QTc-prolonging activities of Pentamidine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Maprotiline.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Maprotiline.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved
PerazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Perazine.Approved, Investigational
PerflutrenMaprotiline may increase the QTc-prolonging activities of Perflutren.Approved
PerospironeThe risk or severity of adverse effects can be increased when Maprotiline is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Maprotiline.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Maprotiline.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Phenazocine.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Maprotiline.Approved
PhenibutThe risk or severity of adverse effects can be increased when Maprotiline is combined with Phenibut.Experimental
PheniprazineThe risk or severity of adverse effects can be increased when Pheniprazine is combined with Maprotiline.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Maprotiline.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Maprotiline is combined with Phenoxyethanol.Approved
PhenoxypropazineThe risk or severity of adverse effects can be increased when Phenoxypropazine is combined with Maprotiline.Withdrawn
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Maprotiline.Approved, Vet Approved
PimozideMaprotiline may increase the QTc-prolonging activities of Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Piritramide.Approved, Investigational
PirlindoleThe risk or severity of adverse effects can be increased when Pirlindole is combined with Maprotiline.Approved
PivhydrazineThe risk or severity of adverse effects can be increased when Pivhydrazine is combined with Maprotiline.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pomalidomide.Approved
PramipexoleMaprotiline may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Maprotiline is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Maprotiline can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Prilocaine.Approved
PrimaquineMaprotiline may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Maprotiline.Approved, Vet Approved
ProcainamideMaprotiline may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Maprotiline.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Maprotiline.Approved, Vet Approved
PromazineThe metabolism of Maprotiline can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Promethazine.Approved, Investigational
PropafenoneMaprotiline may increase the QTc-prolonging activities of Propafenone.Approved
PropanididThe risk or severity of adverse effects can be increased when Maprotiline is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Proparacaine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Propericiazine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Maprotiline.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Propoxycaine.Approved
ProthipendylThe risk or severity of adverse effects can be increased when Maprotiline is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Maprotiline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Maprotiline is combined with Proxibarbal.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Maprotiline.Approved
PSD502The risk or severity of adverse effects can be increased when Maprotiline is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Maprotiline.Approved, Illicit
QuetiapineMaprotiline may increase the QTc-prolonging activities of Quetiapine.Approved
QuinidineThe metabolism of Maprotiline can be decreased when combined with Quinidine.Approved, Investigational
QuinineMaprotiline may increase the QTc-prolonging activities of Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ramelteon.Approved, Investigational
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Maprotiline.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Maprotiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Maprotiline.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Maprotiline.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Maprotiline.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Maprotiline.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ritanserin.Investigational
RitonavirThe metabolism of Maprotiline can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Maprotiline is combined with Rizatriptan.Approved
RolapitantThe metabolism of Maprotiline can be decreased when combined with Rolapitant.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Romifidine.Vet Approved
RopiniroleMaprotiline may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ropivacaine.Approved
RotigotineMaprotiline may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Maprotiline can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Maprotiline.Approved
SafrazineThe risk or severity of adverse effects can be increased when Safrazine is combined with Maprotiline.Withdrawn
SaquinavirMaprotiline may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Maprotiline.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Maprotiline.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Maprotiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Maprotiline is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Maprotiline.Approved, Vet Approved
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Maprotiline.Approved
SimeprevirThe metabolism of Maprotiline can be decreased when combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved
SotalolMaprotiline may increase the QTc-prolonging activities of Sotalol.Approved
StiripentolThe metabolism of Maprotiline can be decreased when combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Maprotiline.Approved, Investigational
SulfisoxazoleMaprotiline may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Maprotiline.Approved, Investigational
SuvorexantMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Maprotiline is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Maprotiline is combined with Tasimelteon.Approved, Investigational
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Maprotiline.Approved
TelavancinMaprotiline may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinMaprotiline may increase the QTc-prolonging activities of Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Maprotiline.Approved, Investigational
Tenofovir disoproxilThe metabolism of Maprotiline can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerbinafineThe metabolism of Maprotiline can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe serum concentration of Maprotiline can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineMaprotiline may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Maprotiline is combined with Tetrodotoxin.Investigational
ThalidomideMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Maprotiline can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Maprotiline is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Maprotiline is combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Maprotiline is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Thioproperazine.Approved
ThioridazineThe metabolism of Maprotiline can be decreased when combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Maprotiline.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Maprotiline.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Maprotiline can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Tilidine.Experimental
TipranavirThe metabolism of Maprotiline can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Maprotiline.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Maprotiline.Approved, Withdrawn
ToloxatoneThe risk or severity of adverse effects can be increased when Toloxatone is combined with Maprotiline.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Maprotiline.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Maprotiline.Approved, Investigational
ToremifeneMaprotiline may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Maprotiline.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Maprotiline.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Maprotiline.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Maprotiline.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Maprotiline.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Maprotiline is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Maprotiline is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Maprotiline.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Maprotiline is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Maprotiline.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Maprotiline.Approved
TropisetronTropisetron may increase the serotonergic activities of Maprotiline.Approved, Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Maprotiline is combined with Valproic Acid.Approved, Investigational
VandetanibMaprotiline may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibThe serum concentration of Maprotiline can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Maprotiline.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Maprotiline is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Maprotiline.Approved
VincristineThe excretion of Vincristine can be decreased when combined with Maprotiline.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Maprotiline is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Maprotiline.Approved, Investigational
XenonThe risk or severity of adverse effects can be increased when Maprotiline is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Maprotiline.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Maprotiline is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Zimelidine.Withdrawn
ZiprasidoneMaprotiline may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Maprotiline is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Maprotiline.Approved, Investigational
ZolpidemMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Maprotiline.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Maprotiline.Approved
ZotepineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Zotepine.Approved, Investigational
ZucapsaicinThe metabolism of Maprotiline can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolMaprotiline may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals. Limit caffeine intake.

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0015069
KEGG Drug
D02566
KEGG Compound
C07107
PubChem Compound
4011
PubChem Substance
46508358
ChemSpider
3871
BindingDB
35228
ChEBI
6690
ChEMBL
CHEMBL21731
Therapeutic Targets Database
DAP001150
PharmGKB
PA450322
IUPHAR
2402
Guide to Pharmacology
GtP Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Maprotiline
ATC Codes
N06AA21 — Maprotiline
AHFS Codes
  • 28:16.04.28 — Tricyclics and Other Norepinephrine-reuptake Inhibitors
MSDS
Download (64.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1

Pharmacoeconomics

Manufacturers
  • Novartis pharmaceuticals corp
  • American therapeutics inc
  • Mylan pharmaceuticals inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
TabletOral25 mg
TabletOral50 mg
TabletOral75 mg
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral50 mg/1
Tablet, film coatedOral75 mg/1
TabletOral10 mg
Prices
Unit descriptionCostUnit
Novo-Maprotiline 75 mg Tablet1.54USD tablet
Maprotiline HCl 75 mg tablet1.25USD tablet
Novo-Maprotiline 50 mg Tablet1.13USD tablet
Maprotiline 75 mg tablet0.91USD tablet
Maprotiline HCl 50 mg tablet0.86USD tablet
Maprotiline 50 mg tablet0.79USD tablet
Maprotiline HCl 25 mg tablet0.73USD tablet
Maprotiline 25 mg tablet0.69USD tablet
Novo-Maprotiline 25 mg Tablet0.6USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)93 °CPhysProp
water solubilitySlightly solubleNot Available
logP5.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00015 mg/mLALOGPS
logP4.89ALOGPS
logP4.37ChemAxon
logS-6.3ALOGPS
pKa (Strongest Basic)10.54ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity99.3 m3·mol-1ChemAxon
Polarizability33.57 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9903
Caco-2 permeable+0.7214
P-glycoprotein substrateSubstrate0.7836
P-glycoprotein inhibitor IInhibitor0.7667
P-glycoprotein inhibitor IIInhibitor0.7206
Renal organic cation transporterInhibitor0.6502
CYP450 2C9 substrateNon-substrate0.7898
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.5216
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8931
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.855
Ames testNon AMES toxic0.7713
CarcinogenicityNon-carcinogens0.9204
BiodegradationNot ready biodegradable0.8913
Rat acute toxicity2.5307 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7016
hERG inhibition (predictor II)Inhibitor0.8652
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-0f6x-9560000000-f263c228ecd4df5d7e73
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0090000000-7a66545f7844123eba51
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0fb9-0090000000-c3b045151955339e59cc
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0gb9-0590000000-bfeab480527e9e5cb70a
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0930000000-406a233a8ad8a3b5d463
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-002f-0920000000-d86cbfa85ef229dfed53
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-004i-0090000000-1a2bf3822fc21e2f8460
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0fb9-0190000000-cf4d09e63ae607c3f690
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0gb9-1690000000-32657b0912154e5e6eb5
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00kf-1940000000-176ec01fb7ad9b4a11ca
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-1920000000-a721293bed4aff937490
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-1910000000-f2d680cb6b1ab57df4bd
MS/MS Spectrum - , positiveLC-MS/MSsplash10-004i-0390000000-ae291d01fb28cc38d1de

Taxonomy

Description
This compound belongs to the class of organic compounds known as anthracenes. These are organic compounds containing a system of three linearly fused benzene rings.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Anthracenes
Sub Class
Not Available
Direct Parent
Anthracenes
Alternative Parents
Tetralins / Aralkylamines / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Anthracene / Tetralin / Aralkylamine / Secondary amine / Secondary aliphatic amine / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative / Organonitrogen compound / Amine
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
anthracenes (CHEBI:6690)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Norepinephrine:sodium symporter activity
Specific Function
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A2
Uniprot ID
P23975
Uniprot Name
Sodium-dependent noradrenaline transporter
Molecular Weight
69331.42 Da
References
  1. Saba W, Valette H, Schollhorn-Peyronneau MA, Coulon C, Ottaviani M, Chalon S, Dolle F, Emond P, Halldin C, Helfenbein J, Madelmont JC, Deloye JB, Guilloteau D, Bottlaender M: [11C]LBT-999: a suitable radioligand for investigation of extra-striatal dopamine transporter with PET. Synapse. 2007 Jan;61(1):17-23. [PubMed:17068778]
  2. Arai S, Morita K, Kitayama S, Kumagai K, Kumagai M, Kihira K, Dohi T: Chronic inhibition of the norepinephrine transporter in the brain participates in seizure sensitization to cocaine and local anesthetics. Brain Res. 2003 Feb 21;964(1):83-90. [PubMed:12573515]
  3. Cloonan SM, Drozgowska A, Fayne D, Williams DC: The antidepressants maprotiline and fluoxetine have potent selective antiproliferative effects against Burkitt lymphoma independently of the norepinephrine and serotonin transporters. Leuk Lymphoma. 2010 Mar;51(3):523-39. doi: 10.3109/10428190903552112. [PubMed:20141432]
  4. Dronjak S, Spasojevic N, Gavrilovic L, Varagic V: Effects of noradrenaline and serotonin reuptake inhibitors on pituitary-adrenocortical and sympatho-adrenomedullar system of adult rats. Neuro Endocrinol Lett. 2007 Oct;28(5):614-20. [PubMed:17984940]
  5. Mochizucki D: Serotonin and noradrenaline reuptake inhibitors in animal models of pain. Hum Psychopharmacol. 2004 Oct;19 Suppl 1:S15-9. [PubMed:15378668]
Details
2. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Noguchi S, Inukai T, Kuno T, Tanaka C: The suppression of olfactory bulbectomy-induced muricide by antidepressants and antihistamines via histamine H1 receptor blocking. Physiol Behav. 1992 Jun;51(6):1123-7. [PubMed:1353628]
  2. Cavero I, Lefevre-Borg F, Roach AG: Effects of mianserin, desipramine and maprotiline on blood pressure responses evoked by acetylcholine, histamine and 5-hydroxytryptamine in rats. Br J Pharmacol. 1981 Sep;74(1):143-8. [PubMed:6115693]
  3. Kanba S, Richelson E: Histamine H1 receptors in human brain labelled with [3H]doxepin. Brain Res. 1984 Jun 18;304(1):1-7. [PubMed:6146381]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. El-Fakahany E, Richelson E: Antagonism by antidepressants of muscarinic acetylcholine receptors of human brain. Br J Pharmacol. 1983 Jan;78(1):97-102. [PubMed:6297650]
  2. Golds PR, Przyslo FR, Strange PG: The binding of some antidepressant drugs to brain muscarinic acetylcholine receptors. Br J Pharmacol. 1980 Mar;68(3):541-9. [PubMed:7052344]
  3. Doggrell SA, Vincent L: The postsynaptic effects of antidepressant drugs in the rat anococcygeus muscle. J Pharm Pharmacol. 1981 Nov;33(11):720-4. [PubMed:6118411]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. El-Fakahany E, Richelson E: Antagonism by antidepressants of muscarinic acetylcholine receptors of human brain. Br J Pharmacol. 1983 Jan;78(1):97-102. [PubMed:6297650]
  2. Golds PR, Przyslo FR, Strange PG: The binding of some antidepressant drugs to brain muscarinic acetylcholine receptors. Br J Pharmacol. 1980 Mar;68(3):541-9. [PubMed:7052344]
  3. Doggrell SA, Vincent L: The postsynaptic effects of antidepressant drugs in the rat anococcygeus muscle. J Pharm Pharmacol. 1981 Nov;33(11):720-4. [PubMed:6118411]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. El-Fakahany E, Richelson E: Antagonism by antidepressants of muscarinic acetylcholine receptors of human brain. Br J Pharmacol. 1983 Jan;78(1):97-102. [PubMed:6297650]
  2. Golds PR, Przyslo FR, Strange PG: The binding of some antidepressant drugs to brain muscarinic acetylcholine receptors. Br J Pharmacol. 1980 Mar;68(3):541-9. [PubMed:7052344]
  3. Doggrell SA, Vincent L: The postsynaptic effects of antidepressant drugs in the rat anococcygeus muscle. J Pharm Pharmacol. 1981 Nov;33(11):720-4. [PubMed:6118411]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM4
Uniprot ID
P08173
Uniprot Name
Muscarinic acetylcholine receptor M4
Molecular Weight
53048.65 Da
References
  1. El-Fakahany E, Richelson E: Antagonism by antidepressants of muscarinic acetylcholine receptors of human brain. Br J Pharmacol. 1983 Jan;78(1):97-102. [PubMed:6297650]
  2. Golds PR, Przyslo FR, Strange PG: The binding of some antidepressant drugs to brain muscarinic acetylcholine receptors. Br J Pharmacol. 1980 Mar;68(3):541-9. [PubMed:7052344]
  3. Doggrell SA, Vincent L: The postsynaptic effects of antidepressant drugs in the rat anococcygeus muscle. J Pharm Pharmacol. 1981 Nov;33(11):720-4. [PubMed:6118411]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM5
Uniprot ID
P08912
Uniprot Name
Muscarinic acetylcholine receptor M5
Molecular Weight
60073.205 Da
References
  1. El-Fakahany E, Richelson E: Antagonism by antidepressants of muscarinic acetylcholine receptors of human brain. Br J Pharmacol. 1983 Jan;78(1):97-102. [PubMed:6297650]
  2. Golds PR, Przyslo FR, Strange PG: The binding of some antidepressant drugs to brain muscarinic acetylcholine receptors. Br J Pharmacol. 1980 Mar;68(3):541-9. [PubMed:7052344]
  3. Doggrell SA, Vincent L: The postsynaptic effects of antidepressant drugs in the rat anococcygeus muscle. J Pharm Pharmacol. 1981 Nov;33(11):720-4. [PubMed:6118411]
Kind
Protein group
Organism
Human
Pharmacological action
No
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...

Components:
References
  1. Buckley NA, McManus PR: Can the fatal toxicity of antidepressant drugs be predicted with pharmacological and toxicological data? Drug Saf. 1998 May;18(5):369-81. [PubMed:9589848]
  2. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Peroutka SJ, Lebovitz RM, Snyder SH: Two distinct central serotonin receptors with different physiological functions. Science. 1981 May 15;212(4496):827-9. [PubMed:7221567]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Serotonin receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-...
Gene Name
HTR2C
Uniprot ID
P28335
Uniprot Name
5-hydroxytryptamine receptor 2C
Molecular Weight
51820.705 Da
References
  1. Peroutka SJ, Lebovitz RM, Snyder SH: Two distinct central serotonin receptors with different physiological functions. Science. 1981 May 15;212(4496):827-9. [PubMed:7221567]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Serotonin receptor activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor ...
Gene Name
HTR7
Uniprot ID
P34969
Uniprot Name
5-hydroxytryptamine receptor 7
Molecular Weight
53554.43 Da
References
  1. Lucchelli A, Santagostino-Barbone MG, D'Agostino G, Masoero E, Tonini M: The interaction of antidepressant drugs with enteric 5-HT7 receptors. Naunyn Schmiedebergs Arch Pharmacol. 2000 Sep;362(3):284-9. [PubMed:10997731]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Binder
General Function
Potassium channel regulator activity
Specific Function
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name
DRD2
Uniprot ID
P14416
Uniprot Name
D(2) dopamine receptor
Molecular Weight
50618.91 Da
References
  1. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Thioesterase binding
Specific Function
Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...

Components:
References
  1. Richelson E, Nelson A: Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther. 1984 Jul;230(1):94-102. [PubMed:6086881]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Brachtendorf L, Jetter A, Beckurts KT, Holscher AH, Fuhr U: Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. Pharmacol Toxicol. 2002 Mar;90(3):144-9. [PubMed:12071336]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da
References
  1. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173]
  2. Eap CB, Cuendet C, Baumann P: Selectivity in the binding of psychotropic drugs to the variants of alpha-1 acid glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 1988 Feb;337(2):220-4. [PubMed:3368020]
  3. Lynn K, Braithwaite R, Dawling S, Rosser R: Comparison of the serum protein binding of maprotiline and phenytoin in uraemic patients on haemodialysis. Eur J Clin Pharmacol. 1981 Jan;19(1):73-7. [PubMed:7461027]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524]
  2. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103]

Drug created on June 13, 2005 07:24 / Updated on February 13, 2018 09:41